August 8, 2017 09:50 AM EDT
R&D

Es­pe­ri­on shares bounce up on an ef­fec­tive triplet ap­proach to slash­ing LDL

John Carroll

Editor & Founder

Es­pe­ri­on shares $ES­PR got a bounce out of a Phase II up­date on a triple com­bi­na­tion drug us­ing be­mpe­doic acid in re­duc­ing LDL. A com­bi­na­tion …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
ENDPOINTS CAREERS

Global Head of Marketing

Bachem

Bubendorf, BL, Switzerland

TRENDING NOW

Pfiz­er says it has at least $10B avail­able for deals in 2025, with a fo­cus on pipeline

New study will try to stop Alzheimer’s decades be­fore it be­gins, us­ing ex­per­i­men­tal Eli Lil­ly drug

Am­gen an­nounces hold on Phase 1 obe­si­ty can­di­date, pipeline cuts

We’re about to find out which RFK Jr. will show up at HHS

Astel­las shakes up man­age­ment de­spite im­pres­sive nine-month earn­ings

Mer­ck CEO says he’s con­fi­dent in growth de­spite Gar­dasil ‘head­wind’

A service from the Financial Times